Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
VSTM's Cash to Debt is ranked higher than
97% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. VSTM: No Debt )
VSTM' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
VSTM's Interest Coverage is ranked higher than
73% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VSTM: No Debt )
VSTM' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 18.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -48.40
VSTM's ROE (%) is ranked higher than
63% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. VSTM: -48.40 )
VSTM' s 10-Year ROE (%) Range
Min: -35.35   Max: -35.08
Current: -48.4

-35.35
-35.08
ROA (%) -44.72
VSTM's ROA (%) is ranked higher than
62% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. VSTM: -44.72 )
VSTM' s 10-Year ROA (%) Range
Min: -34.42   Max: -23.18
Current: -44.72

-34.42
-23.18
ROC (Joel Greenblatt) (%) -3240.97
VSTM's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. VSTM: -3240.97 )
VSTM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6561.33   Max: -1932.02
Current: -3240.97

-6561.33
-1932.02
» VSTM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

VSTM Guru Trades in Q3 2013

Steven Cohen 1,114 sh (New)
Jean-Marie Eveillard 492,703 sh (New)
Jim Simons 55,700 sh (+216.48%)
» More
Q4 2013

VSTM Guru Trades in Q4 2013

Paul Tudor Jones 17,219 sh (New)
Jean-Marie Eveillard 511,254 sh (+3.77%)
Jim Simons Sold Out
Steven Cohen Sold Out
» More
Q1 2014

VSTM Guru Trades in Q1 2014

Jean-Marie Eveillard 511,254 sh (unchged)
Paul Tudor Jones 11,685 sh (-32.14%)
» More
Q2 2014

VSTM Guru Trades in Q2 2014

Jean-Marie Eveillard 512,254 sh (+0.2%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with VSTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-09-30 New Buy0.02%$12.71 - $17.57 $ 8.96-39%492703
Jean-Marie Eveillard 2013-06-30 Sold Out $8.79 - $13.88 $ 8.96-11%0
Jean-Marie Eveillard 2012-09-30 Add 54.31%$8.02 - $11.5 $ 8.96-6%52331
Jean-Marie Eveillard 2012-06-30 New Buy$9.3 - $11.11 $ 8.96-11%33912
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.40
VSTM's P/B is ranked higher than
87% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. VSTM: 2.40 )
VSTM' s 10-Year P/B Range
Min: 0   Max: 4.9
Current: 2.4

0
4.9
EV-to-EBIT -3.56
VSTM's EV-to-EBIT is ranked higher than
82% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. VSTM: -3.56 )
VSTM' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -3.56

Current Ratio 12.65
VSTM's Current Ratio is ranked higher than
91% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. VSTM: 12.65 )
VSTM' s 10-Year Current Ratio Range
Min: 11.13   Max: 30.79
Current: 12.65

11.13
30.79
Quick Ratio 12.65
VSTM's Quick Ratio is ranked higher than
92% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. VSTM: 12.65 )
VSTM' s 10-Year Quick Ratio Range
Min: 11.13   Max: 30.79
Current: 12.65

11.13
30.79

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.50
VSTM's Price/Net Cash is ranked higher than
96% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. VSTM: 2.50 )
VSTM' s 10-Year Price/Net Cash Range
Min: 2.7   Max: 5.77
Current: 2.5

2.7
5.77
Price/Net Current Asset Value 2.50
VSTM's Price/Net Current Asset Value is ranked higher than
96% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. VSTM: 2.50 )
VSTM' s 10-Year Price/Net Current Asset Value Range
Min: 2.7   Max: 5.73
Current: 2.5

2.7
5.73
Price/Tangible Book 2.30
VSTM's Price/Tangible Book is ranked higher than
91% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. VSTM: 2.30 )
VSTM' s 10-Year Price/Tangible Book Range
Min: 1.98   Max: 3.87
Current: 2.3

1.98
3.87

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:2VS.Germany
Verastem Inc was incorporated under the laws of the State of Delaware in August 2010. The company is a biopharmaceutical company focused on discovering and developing proprietary small molecule drugs targeting cancer stem cells in breast and other cancers along with proprietary companion diagnostics. It licenses its EMT technology from the Whitehead Institute for Biomedical Research, an affiliate of the Massachusetts Institute of Technology, or MIT, and the President and Fellows of Harvard College, or Harvard. Its advanced product candidates are VS-507, VS-4718 and VS-5095. The company is currently evaluating these compounds in preclinical studies as potential therapies for breast and other cancers. Its products include VS-507 - The Company is currently evaluating VS-507 in preclinical studies as a potential therapy for breast cancer. Its scientific co-founders identified VS-507 using the proprietary technology that it license from the Whitehead Institute and published the results in the peer reviewed scientific journal Cell in 2009. The company holds an exclusive license from the Whitehead Institute for use of VS-507 in treating cancer. The company expects to initiate a clinical trial with VS-507 over the next 12 to 15 months. It is currently evaluating VS-4718 and VS-5095 as potential therapies for cancers with a percentage of CSCs. The company identified the CSC-targeted activity of these compounds using its proprietary technology and hold worldwide exclusive rights to these compounds and their use. It expect to initiate a clinical trial with one of either VS-4718 or VS-5095 over the next 12 to 15 months. It believe VS-4718 and VS-5095 target CSCs through inhibition of FAK signaling. FAK expression is greater in many tumor types compared to normal tissue, particularly in cancers that have an invasive and metastatic capability. The contact between epithelial cancer cells and connective tissue stimulates FAK signaling. However, epithelial cancer cells that undergo EMT acquire the ability to survive in the absence of contact with connective tissue. The company thinks that FAK signaling in CSCs may be maintained through alternative mechanisms, thus providing CSCs the ability to survive in the absence of cell contact. Accordingly, it thinks that FAK signaling may be a central component of CSC biology that allows CSCs to survive after exiting from a tumor mass and enable metastasis to other sites in the body. It has initiated NCE programs on more than 10 series of chemical compounds identified using its proprietary EMT technology along with throughput screening methods. In addition, it has synthesized several drug candidates that are chemically similar to VS-507 and are currently optimizing their activity to block Wnt/beta-catenin signaling and induce selective killing of CSCs. The company faces competition from other pharmaceutical companies including Astellas Pharma Inc., Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, Boehringer In
» More Articles for VSTM

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
VERASTEM, INC. Financials Aug 19 2014
The Negative Impact Of Pfizer's Mergers And Budget Cuts On Cancer R&D Aug 19 2014
VERASTEM, INC. Files SEC form 10-Q, Quarterly Report Aug 07 2014
Verastem Reports Second Quarter 2014 Financial and Corporate Results Aug 07 2014
Verastem Presents Results and Updated Development Plans at Annual Research and Development Day Jul 10 2014
Verastem, Inc. (NASDAQ: VSTM) to Ring The NASDAQ Stock Market Closing Bell Jul 09 2014
Verastem (VSTM) Crumbles: Stock Falls by 6.1% Jul 09 2014
Verastem to Ring the NASDAQ Stock Market Closing Bell and Host Annual Research and Development Day... Jul 08 2014
Verastem downgraded to Perform from Outperform at Oppenheimer Jul 07 2014
The Potential of Targeting Cancer Stem Cells Through FAK Inhibition in Mesothelioma Reported in... Jun 24 2014
Verastem to Present at Upcoming Conferences Jun 10 2014
Verastem Presents Updated Clinical Data from VS-6063 and Paclitaxel Combination Phase 1/1b Study in... Jun 02 2014
Verastem (VSTM) in Focus: Stock Adds 14% in Session May 28 2014
Verastem publishes data on targeting mesothelioma cancer stem cells May 27 2014
Verastem Publishes Scientific Data on Targeting Mesothelioma Cancer Stem Cells in Science... May 27 2014
Verastem to Present at the 2014 ASCO Annual Meeting May 20 2014
Verastem to Present at Upcoming Investor Conferences May 14 2014
VERASTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... May 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK